Back to results
US 12,583,856 B2Granted
Inhibitors of protein kinase A
AssigneeBlueprint Medicines Corporation
InventorsNeil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
Life of this patent
Estimating the term…
Abstract
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
Claims20
A compound of Formula (I):
- a pharmaceutically acceptable salt thereof, and/or a solvate of any of the foregoing, wherein:
- X is chosen from CH and N;
- Y is chosen from CH and N, provided that X and Y are not both N;
- R1 is chosen from H, halogens, and C1-C4 alkyls;
- and
- R2 is chosen from optionally substituted indane and optionally substituted chromane, wherein each optional substituent is independently chosen from halogens, hydroxyl, C1-C4 alkyls, C1-C4 haloalkyls, 4-8-membered monocyclic heterocycles, 4-8-membered bicyclic heterocycles, NR3R4, and OC1-C4 alkyls,
- wherein:
- each 4-8-membered monocyclic heterocycle, 4-8-membered bicyclic heterocycle, C1-C4 alkyl, and OC1-C4 alkyl is optionally substituted with one to three groups independently chosen from C1-C4 alkyls, C1-C4 hydroxyalkyls, C1-C4 haloalkyls, OC1-C4 alkyls, OC1-C4 hydroxyalkyls, halogens, hydroxyl, and C (O) NR5R6;
- each R3 and R4 is independently chosen from hydrogen and C1-C4 alkyls;
- and
- each R5 and R6 is independently chosen from hydrogen and C1-C4 alkyls.
8 more elements
Dependencies are inferred from the claim text.